XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and produced by
Each patient will be followed for 18 months with efficacy readings every six months. The primary goal is to show that XSTEM is safe, but also to investigate preliminary efficacy signals, such as reduced pain, reduced degradation of articular cartilage, regeneration of damaged cartilage and improved joint function. Safety data from all dose levels and up to 12 months efficacy data from the lowest dose level are expected in 2023.
"We are pleased that the study with XSTEM for the treatment of knee osteoarthritis is progressing so well and that we are seeing indications of the effect of the treatment, although we are still at an early stage. We now look forward to establishing the safety from all dose levels and continuing to evaluate the effect of the treatment", says
© Modular Finance, source